Factor This Power Engineering
Live Events
DTECH® Events
POWERGENâ¢
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Galapagos NV
< Previous
1
2
3
Next >
Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases
March 23, 2026
From
Galapagos NV
Via
GlobeNewswire
Galapagos Receives Transparency Notification from Bank of America
March 17, 2026
From
Galapagos NV
Via
GlobeNewswire
Galapagos Receives Transparency Notifications from Bank of America
March 10, 2026
From
Galapagos NV
Via
GlobeNewswire
Galapagos Creates New Subscription Right Plan
March 06, 2026
From
Galapagos NV
Via
GlobeNewswire
Galapagos Appoints Tania Philipp as Chief Human Resources Officer
March 05, 2026
From
Galapagos NV
Via
GlobeNewswire
Galapagos Receives Transparency Notifications from Bank of America
March 04, 2026
From
Galapagos NV
Via
GlobeNewswire
Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
February 23, 2026
From
Galapagos NV
Via
GlobeNewswire
Galapagos Welcomes Dr. Paulo Fontoura to its Board of Directors
February 19, 2026
From
Galapagos NV
Via
GlobeNewswire
Galapagos Receives Transparency Notification from Bank of America
February 16, 2026
From
Galapagos NV
Via
GlobeNewswire
Galapagos Receives Transparency Notifications from Bank of America
February 10, 2026
From
Galapagos NV
Via
GlobeNewswire
Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities
January 05, 2026
From
Galapagos NV
Via
GlobeNewswire
Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus
December 18, 2025
From
Galapagos NV
Via
GlobeNewswire
Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025
December 08, 2025
From
Galapagos NV
Via
GlobeNewswire
Galapagos Receives Transparency Notifications from Bank of America
November 26, 2025
From
Galapagos NV
Via
GlobeNewswire
Galapagos to Present New Data from Cell Therapy Program at ASH 2025
November 03, 2025
From
Galapagos NV
Via
GlobeNewswire
Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development
October 30, 2025
From
Galapagos NV
Via
GlobeNewswire
Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update
November 05, 2025
From
Galapagos NV
Via
GlobeNewswire
Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors
October 23, 2025
From
Galapagos NV
Via
GlobeNewswire
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company’s Ongoing Transformation
October 21, 2025
From
Galapagos NV
Via
GlobeNewswire
Galapagos Announces Appointment of Fred Blakeslee as General Counsel
October 16, 2025
From
Galapagos NV
Via
GlobeNewswire
Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business
October 01, 2025
From
Galapagos NV
Via
GlobeNewswire
Galapagos Creates New Subscription Right Plan
August 07, 2025
From
Galapagos NV
Via
GlobeNewswire
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
August 06, 2025
From
Galapagos NV
Via
GlobeNewswire
Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation
July 23, 2025
From
Galapagos NV
Via
GlobeNewswire
Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors
July 23, 2025
From
Galapagos NV
Via
GlobeNewswire
Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update
July 23, 2025
From
Galapagos NV
Via
GlobeNewswire
Galapagos Appoints Aaron Cox as Chief Financial Officer
June 23, 2025
From
Galapagos NV
Via
GlobeNewswire
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101
June 18, 2025
From
Galapagos NV
Via
GlobeNewswire
Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL
June 12, 2025
From
Galapagos NV
Via
GlobeNewswire
Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101
May 14, 2025
From
Galapagos NV
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
